Maximizing the effect of biologics in inflammatory bowel disease

Minerva Gastroenterologica e Dietologica

Volumn 58, Issue 2, 2012, Pages 101-122

  Souto Rodriguez, R ^a   Swoger, J M ^b   Barreiro De Acosta, M ^a   Regueiro, M ^b  

^a Instituto de Salud Carlos III   (Spain)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Biologic therapy; Colitis, ulcerative; Crohn disease; Inflammatory bowel diseases

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DRUG ANTIBODY; HYDROCORTISONE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO;

ADD ON THERAPY; ANASTOMOTIC STENOSIS; ANTIBODY RESPONSE; BIOLOGICAL THERAPY; CLINICAL PRACTICE; COLON RESECTION; COLONOSCOPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; HEREDITY; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFUSION RELATED REACTION; INTESTINE FISTULA; LOW DRUG DOSE; META ANALYSIS (TOPIC); MONOTHERAPY; OPTIMAL DRUG DOSE; PERIANAL ABSCESS; POLYPHARMACY; PREMEDICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SMALL INTESTINE PERFORATION; STENOSIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; ULCERATIVE COLITIS; WOUND HEALING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL AGENTS; DRUG RESISTANCE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTORS;

EID: 84864775326     PISSN: 1121421X     EISSN: 18271642     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis 2011;17:2366-91.
2. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
4. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
5. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
6. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
7. Sands BE, Anderson FH, Bernstein CN, Chey WJ, Feagan BG, Fedorak RN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
8. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008:CD006893.
9. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrence IC. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25.
10. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
11. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
12. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983-9.
13. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30.
14. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9.
15. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966;11:847-57.
16. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010;16:338-46.
17. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29.
18. Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf 2011;20:838-48.
19. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9.
20. Carter CT, Leher H, Smith P, Smith DB, Waters HC. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care 2011;17:385-92.
21. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
22. Rutgeerts P, D'Haens G, Targan S, Vasilianskas E, Hanauer SB, Present DH et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
23. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G et al. Long-term outcome of treatment with infliximab in 6l4 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
24. Gonzaga JE, Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Zadvornova Y et al. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis 2009;15:1837-43.
25. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7.
26. Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007;13:1093-9.
27. Chaparro M, Panes J, Garcia V, Merino O, Nos P, Domènech E et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012 (in press).
28. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011;106:674-84.
29. Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010;105:2617-25.
30. Kumar S, Ananthakrishnan AN, Zadorova Z, Issa M, Naik A, Perera L. Durability of infliximab in ulcerative colitis: A tertiary center experience. Gastroenterology 2010;138.
31. Barreiro-de Acosta M, Lorenzo A, Mera J, Dominguez-Munoz JE. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009:3:271-6.
32. Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011;34:1-10.
33. Etchevers MJ, Ordas I, Ricart E. Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach. Drugs 2010;70:109-20.
34. Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:501-5.
35. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53.
36. Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr Gastroenterol Rep 2010;12:471-8.
37. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124:917-24.
38. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
39. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54.
40. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D et al. Influence of trough serum levels and immunogenicity on longterm outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
41. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
42. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007;56:1226-31.
43. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with lowdose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
44. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40:723-51.
45. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010;48:297-308.
46. van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TC, Dijkmans BA et al. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes Immun 2010;11:622-9.
47. Arijs I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009;58:1612-9.
48. Arijs I, Quintens R, Van Lommel L, Van Steen K, De Hertogh G, Lemaire K et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010;16:2090-8.
49. Agnholt J, Kaltoft K. In situ activated intestinal T cells expanded in vitro-without addition of antigen-produce IFN-gamma and IL-10 and preserve their function during growth. Exp Clin Immunogenet 2011;18:213-25.
50. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006;23:451-63.
51. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42.
52. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
53. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301.
54. Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
55. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerisch J, Panés J et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-82.
56. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H et al. Early combined immuno suppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7.
57. Lin KK, Velayos F, Fisher E, Terdiman JP. Durability of Infliximab Dose Intensification in Crohn's Disease. Dig Dis Sci 2011 [Epub ahead of print].
58. Chaparro M, Panes J, Garcia V, Mañosa M, Esteve M, Merino O et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol 2011;45:113-8.
59. Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis 2011 [Epub ahead of print].
60. Chaparro M, Martinez-Montiel P, Van Domselaar M, Bermejo F, Pérez-Calle JL, Casis B et al. Intensification of infliximab (IFX) therapy in Crohn's disease: Efficacy and safety. Gastroenterology 2008;134:A-664 (abstract).
61. Kopylov U, Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011;33:349-57.
62. Sandborn WJ, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011;17:141-51.
63. Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8:688-95.
64. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen O, Hanauer SB, McColm J et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
65. Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010;8:696-702.
66. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38.
67. Ho GT, Smith L, Aitken S, Lee HM, Ting T, Fennell J et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008;27:308-15.
68. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007;25:675-80.
69. Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut 2011 [Epub ahead of print].
70. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010;32:384-93.
71. Taxonera C, Estelles J, Fernandez-Blanco I, Merino O, Marín-Jiménez I, Barreiro-de Acosta M et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011;33:340-8.
72. Dignass A, Van Assche G, Lindsay JO, Lèmann M, Söderholm J, Colombel JF et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010;4:28-62.
73. Afif W, Loftus EV, Jr., Faubion WA, Kane SV, Bruining DH, Hansen KA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:1133-9.
74. Pariente B, de Chambrun GP, Krysiek R, Desroches M, Louis G, De Cassan et al. Trough levels and anti-bodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011 [Epub ahead of print].
75. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
76. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210-26.
77. Hanauer S, D'Haens G, Colombel F. Sustained clinical remission in patients with moderate to severe Crohn's disease with adalimumab, regardless of anti-TNF history or concomitant immunosuppressant therapy. Am J Gastroenterol 2006;101:S-457 (abstract).
78. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83.
79. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003;17:1451-7.
80. Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002;123:707-13.
81. Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005:37:577-83.
82. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
83. Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 2003:98:608-12.
84. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7.
85. Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010;59:1363-8.
86. Feagan B, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponisch et al. Methotrexate for the prevention of antibodies to infliximab in patients with Crohn's disease. Gastroenterology 2010;138.
87. Zadvornova Y, Ananthakrishnan AN, Stein DJ, Skaros S, Johnson K, Naik AS et al. Infliximab monotherapy vs. combined infliximab-immunomodulator therapy in ulcerative colitis. Gastroenterology 2010;138.
88. Panaccione R, Ghosh S, Middleton S, Marquez JR, Khalif I, Flint L et al. Infliximab, Azathioprine, or Infliximab + Azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial. Gastroenterology 2011;140.
89. Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease: top-down or step-up? Dig Dis 2007;25:260-6.
90. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
91. Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007;42:602-10.
92. Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol 2010;8:655-9.
93. Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012;18:174-9.
94. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8.
95. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010;105:1142-9.
96. Louis E, Vernier-Massouille G, Grimaud JC. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 2008;57:A66 (abstract).